Internal biochemical sensing device

• US 20070010726A1
• Filed: 02/08/2006
• Published: 01/11/2007
• Est. Priority Date: 10/02/2002
• Status: Abandoned Application

• Current Assignee: The Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California (University of Southern California)
• Original Assignee: The Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California (University of Southern California)
• Inventors: Marcu, Laura, Blanco, Cesar, George, Thomas, Loeb, Gerald
• Application Number:
  US11/351,158
• Publication Number:
  US 20070010726A1
• Time in Patent Office: Days
• US Class Current: 600/317
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14542 for measuring blood gases A61B5/14551 takes precedence
• CPC Class Codes: A61B 5/1459 invasive, e.g. introduced into the body by a catheter A61B5/1464 takes precedence
• CPC Class Codes: A61B 5/415 the glands, e.g. tonsils, adenoids or thymus
• CPC Class Codes: A61B 5/418 lymph vessels, ducts or nodes
• CPC Class Codes: G01N 2021/7786 Fluorescence
• CPC Class Codes: G01N 21/7703 using reagent-clad optical fibres or optical waveguides using measurement of total internal reflection or attenuated total reflection G01N21/552; optical fibres or waveguides per se G02B

Abstract

A biosensing device for detecting biological analytes, and methods of use and manufacture, are disclosed. The device includes a biosensing element that can remain implanted for extended periods of time. The biosensing element is connected to an optical fiber terminating outside of the body. The optical fiber is also connected to an information analyzer. The information analyzer receives light from the reaction of fluorescent molecules in the biosensing element. The biosensing device can be used to detect and analyze the effectiveness of chemotherapy agents and molecules associated with various diseases.

Claims

1. A device for detecting an analyte from within a patient'"'"'s body, comprising:

an optical fiber having;

a first end; and

a second end configured to connect to an analyzer; and

a biosensing material attached to the first end comprising;

a polymer matrix; and

tubulin, that binds with a chemotherapeutic agent, covalently bound to the polymer matrix.

2. The device of claim 1, wherein the polymer matrix comprises polyethylene glycol.

3. The device of claim 1, wherein the first end of the optical fiber further comprises a chemically altered adhesion region to which the biosensing material is attached.

4. The device of claim 1, wherein the first end of the optical fiber further comprises a mechanically altered adhesion region to which the biosensing material is attached.

5. The device of claim 1, wherein the chemotherapeutic agent comprises a mitotic inhibitor.

6. A device for detecting an analyte from within a patient'"'"'s body, comprising:

an optical fiber having;

a first end; and

a second end configured to connect to an analyzer; and

a biosensing material attached to the first end comprising;

a polymer matrix; and

at least one fluorescent molecule covalently bound to the polymer matrix that fluoresces upon binding with at least one molecule indicative of apoptosis.

7. The device of claim 6, wherein the polymer matrix comprises polyethylene glycol.

8. The device of claim 6, wherein the biosensing material comprises a plurality of fluorescent molecules that can fluoresce upon interaction with at least one molecule indicative of apoptosis.

9. The device of claim 6, wherein the first end of the optical fiber further comprises a chemically altered adhesion region to which the biosensing material is attached.

10. The device of claim 6, wherein the first end of the optical fiber further comprises a mechanically altered adhesion region to which the biosensing material is attached.

11. The device of claim 6, wherein the at least one molecule indicative of apoptosis comprises caspase.

12. A method of detecting the effectiveness of a chemotherapy agent, comprising:

a) implanting an optical fiber having an implanted and free end within the patient'"'"'s body such that the implanted end lies within a tumor and the free end protrudes from the patient'"'"'s body, wherein the implanted end comprises biosensing material;

b) delivering a chemotherapy agent to the patient'"'"'s body;

c) delivering light from an analyzer to the biosensing material through the optical fiber;

d) receiving light from the biosensing material through the optical fiber; and

e) analyzing the light that returns to the analyzer from the biosensing material;

wherein the biosensing material comprises;

a polymer matrix; and

at least one fluorescent molecule covalently bound to the polymer matrix and that fluoresces upon interaction with at least one molecule indicative of apoptosis.

13. The method of claim 12, wherein the polymer matrix comprises polyethylene glycol.

14. The method of claim 12, wherein the optical fiber further comprises a chemically altered adhesion region to which the biosensing material is attached.

15. The method of claim 12, wherein the optical fiber further comprises a mechanically altered adhesion region to which the biosensing material is attached.

16. The device of claim 12, wherein the at least one molecule indicative of apoptosis comprises caspase.